Dabigatran bleeds less frequent but more costly

The direct-acting oral anticoagulant dabigatran (Pradaxa) causes less bleeding as a result of over-anticoagulation than warfarin but may be more costly to manage with reversal agents, experience from New Zealand suggests.

A review of more than 550 hospital admissions for over-anticoagulation found that the admission rate was twice as high for warfarin patients than for those taking dabigatran (4.8 vs 2.4 admissions per 100 users).

The review of admissions at Auckland’s North Shore Hospital during 2015 showed that, while